Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 6, 2005, Pages 603-610

  Saito, M ^a   Takada, M ^b   Hirooka, K ^a   Isobe, F ^a   Yasumura, Y ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Candesartan cilexetil; Enalapril maleate; Furosemide; Hyperkalemia; Losartan potassium; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; FUROSEMIDE; LOSARTAN POTASSIUM; NITROGEN; POTASSIUM; SODIUM; SPIRONOLACTONE; UREA; URIC ACID; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; ENALAPRIL; LOOP DIURETIC AGENT; LOSARTAN;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COMBINATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; LOSARTAN; MALE; MIDDLE AGED; POTASSIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE;

EID: 33644968901     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00694.x     Document Type: Article

References (22)

1. Wong PC, Price WA Jr., Chui AT et al. (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP753, an orally active antihypertensive agent. Pharmacology and Experimental Therapeutics, 255, 211 217
2. See S, Stirling AL (2000) Candesartan cilexetil: an angiotensin II-receptor blocker. American Journal of Health-System Pharmacy, 57, 739 746.
3. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine, 327, 685 691.
4. Dahlöf B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 359, 995 1003.
5. Pitt B, Segal R, Martinez FA et al. (1997) Randomized trial of losartan vs. captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet, 349, 747 752.
6. The Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators (2000) Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal, 139, 609 617.
7. Ross EJ (1965) Aldosterone and its antagonists. Clinical Pharmacology and Therapeutics, 6, 65 106.
8. Singer MM, DeGraff AC (1964) Diuretic therapy. VII. Spironolactone. American Heart Journal, 68, 835 837.
9. Liddle GW (1966) Aldosterone antagonists and triamterine. Annals of the New York Academy of Sciences, 139, 466 470.
10. Greenblatt DJ, Koch-Weser J (1973) Adverse reactions to spironolactone. JAMA, 225, 40 43.
11. Slone D, Jick H, Borda I et al. (1966) Drug surveillance utilizing nurse monitors: An epidemiological approach. Lancet, 2, 901 903.
12. Borda IT, Slone D, Jick H (1968) Assessment of adverse reactions within a drug surveillance program. JAMA, 205, 645 647.
13. Slone D, Gaetano LF, Lipworth L, Shapiro S, Lewis GP, Jick H (1969) Computer analysis of epidemiologic data on effect of drugs on hospital patients. Public Health Reports, 84, 39 52.
14. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D (1970) Comprehensive drug surveillance. JAMA, 213, 1455 1460.
15. The Randomized Aldactone Evaluation Study (RALES) Investigators (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study(RALES)). American Journal of Cardiology, 78, 902 907.
16. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709 717.
17. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart, 82, 57 61.
18. Reardon LC, Macpherson DS (1998) Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: How much should we sorry? Archives of Internal Medicine, 158, 26 32.
19. Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet, 355, 637 645.
20. Toto R, Shultz P, Raij L et al. (1998) Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension, 31, 684 691.
21. Malmqvist K, Kahan T, Dahl M (2000) Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil vs. enalapril or hydrochlorothiazide. American Journal of Hypertension, 13, 504 511.
22. Zuschke CA, Keys I, Munger MA et al. (1999) Candesartan cilexetil: Comparison of Once-Daily vs. twice-daily administration for systemic hypertension. Clinical therapeutics, 21, 464 474.